COST-CONSEQUENCE ANALYSIS OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB IN SEROPOSITIVE, EROSIVE EARLY RHEUMATOID ARTHRITIS - BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Marinheiro, P. [1 ]
Faustino, P. [1 ]
Watanabe, S. [2 ]
Lima, P. [2 ]
机构：
[1] Bristol Myers Squibb, New York, NY USA
[2] IQVIA, Sao Paulo, Brazil
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2020年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
111
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS VERSUS INTERMITTENT RENAL REPLACEMENT THERAPY FOR CRITICALLY ILL ACUTE KIDNEY INJURY PATIENTS UNDER THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
    Ramirez, M. G.
    Costa, M. D.
    Costa Carvalho, M.
    VALUE IN HEALTH, 2017, 20 (09) : A867 - A867
  • [32] EFFICACY OF ABATACEPT VERSUS ADALIMUMAB ON THE PROPORTION OF PATIENTS WITH SEROPOSITIVE, EROSIVE EARLY RA ACHIEVING DAS28 (CRP) <2.6 OR VALIDATED MEASURES OF REMISSION: A POST HOC ANALYSIS OF THE 2-YEAR AMPLE TRIAL
    Fleischmann, R.
    Weinblatt, M. E.
    Ahmad, H. A.
    Maldonado, M. A.
    Alemao, E.
    Elbez, Y.
    Schiff, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 916 - 917
  • [33] Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Early, Dual Seropositive Rheumatoid Arthritis, Positive for the Shared Epitope HLA Class II Risk Alleles, and an Inadequate Response to Methotrexate: Results from a Phase 3 Trial
    Weinblatt, Michael
    Emery, Paul
    Bykerk, Vivian
    Cope, Andrew
    Burmester, Gerd
    Tanaka, Yoshiya
    Citera, Gustavo
    Nash, Peter
    Dornic, Quentin
    Kelly, Sheila
    Maldonado, Michael
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5417 - 5419
  • [34] COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Fioratti, C.
    Rachid, M. L.
    Baida, R.
    Decimoni, T.
    Brunelli, M. J.
    VALUE IN HEALTH, 2019, 22 : S618 - S618
  • [35] COST-MINIMIZATION ANALYSIS OF BIOLOGICAL DRUGS IN THE TREATMENT OF SPONDYLOARTHRITIS (PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS) UNDER THE BRAZILIAN PRIVATE HEALTH SYSTEM PERSPECTIVE
    Scaccabarozzi, L.
    Asano, E.
    Monteiro, A. C.
    VALUE IN HEALTH, 2016, 19 (03) : A249 - A249
  • [36] COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Stefani, S. D.
    Santos, M.
    Kashiura, D.
    Leme-Souza, R.
    Fahham, L.
    VALUE IN HEALTH, 2019, 22 : S478 - S479
  • [37] Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective
    Dhanji, Nishit
    Decimoni, Tassia Cristina
    Dyer, Matthew T. D.
    May, Jessica R.
    van de Wetering, Gijs
    Petersohn, Svenja
    Nickel, Katharina
    Silva, Amanda
    Muniz, David Q. B.
    Casagrande D. Oliveira, Ana Paula
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1108 - 1121
  • [38] COMPARING THE LONG-TERM IMPACT ON HEALTHCARE RESOURCES AND COSTS DUE TO SINGLE-PIECE ACRYLIC INTRAOCULAR LENS (IOLS) IMPLANTATION DURING CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM UK HEALTHCARE SYSTEM PERSPECTIVE
    Dhariwal, M.
    Bouchet, C.
    VALUE IN HEALTH, 2018, 21 : S254 - S254
  • [39] COMPARING THE LONG-TERM COSTS ASSOCIATED WITH INTRAOCULAR LENS SELECTION AND ND:YAG LASER CAPSULOTOMY POST-CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM A BELGIAN HEALTHCARE SYSTEM PERSPECTIVE
    Bosgra, O. J.
    Busutil, R.
    Mentens, R.
    Vives, Perez C.
    O'Boyle, D.
    VALUE IN HEALTH, 2019, 22 : S670 - S670
  • [40] COMPARING THE LONG-TERM COSTS ASSOCIATED WITH INTRAOCULAR LENS SELECTION AND ND:YAG LASER CAPSULOTOMY POST-CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM A SPANISH HEALTHCARE SYSTEM PERSPECTIVE
    Belda, J.
    Placeres, J.
    Elvira, J. C.
    Puig, X.
    Perez Vives, C.
    Planas, O.
    O'Boyle, D.
    VALUE IN HEALTH, 2020, 23 : S583 - S583
12345